Cas No.: | 1959588-75-0 |
Chemical Name: | 3-(4-(2-(9H-carbazol-9-yl)ethoxy)phenyl)-2-((2-(4-fluorobenzoyl)phenyl)amino)propanoic acid sodium salt |
Synonyms: | CS-038;CS038 |
SMILES: | [Na+].C([O-])(=O)C(NC1=CC=CC=C1C(=O)C1=CC=C(F)C=C1)CC1=CC=C(OCCN2C3=C(C=CC=C3)C3=C2C=CC=C3)C=C1 |
Formula: | C36H28FN2NaO4 |
M.Wt: | 594.618 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Chiglitazar (CS-038, CS038) is a potent, dual PPARα/γ dual agonist with EC50 of 1.2, 0.08, 1.7 uM for PPARα, PPARγ and PPARδ, respectively; inhibited alanine gluconeogenesis, lowered the hepatic glycogen level in MSG obese rats. Like rosiglitazone, chiglitazar promoted the differentiation of adipocytes and decreased the maximal diameter of adipocytes; Chiglitazar reduced plasma triglyceride, total cholesterol (TCHO), nonesterified fatty acids (NEFA) and low density lipoprotein-cholesterol levels; lowered hepatic triglyceride and TCHO contents; decreased muscular NEFA level. Unlike rosiglitazone, chiglitazar showed significant increase of mRNA expression of PPARα, CPT1, BIFEZ, ACO and CYP4A10 in the liver of MSG obese rats. |